Research Analysts Set Expectations for ENTA FY2025 Earnings

Key Points

• Analysts at Leerink Partners have revised their FY2025 earnings per share estimate for Enanta Pharmaceuticals to ($4.04), down from the previous estimate of ($3.97).
• The company reported Q4 earnings of ($0.85) per share, exceeding the consensus estimate of ($1.25), with revenues of $18.31 million compared to an estimate of $16.21 million.
• Several brokerages have updated their ratings, with JMP Securities raising their price target from $24.00 to $25.00 and upgrading to a "market outperform" rating.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of Enanta Pharmaceuticals in a research note issued to investors on Monday, August 11th. Leerink Partnrs analyst R. Ruiz now forecasts that the biotechnology company will post earnings per share of ($4.04) for the year, down from their previous estimate of ($3.97). The consensus estimate for Enanta Pharmaceuticals' current full-year earnings is ($4.65) per share. Leerink Partnrs also issued estimates for Enanta Pharmaceuticals' Q4 2025 earnings at ($1.07) EPS, FY2026 earnings at ($1.97) EPS, FY2027 earnings at ($1.44) EPS and FY2028 earnings at ($1.21) EPS.

Several other analysts have also recently commented on ENTA. JMP Securities raised their price target on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a "market outperform" rating in a report on Tuesday, August 12th. HC Wainwright started coverage on Enanta Pharmaceuticals in a report on Monday, July 28th. They issued a "buy" rating and a $20.00 target price for the company. Finally, Wall Street Zen upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, June 22nd. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Enanta Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $21.67.

Enanta Pharmaceuticals Trading Up 1.8%

ENTA stock traded up $0.1450 during mid-day trading on Thursday, reaching $8.3150. 158,514 shares of the stock traded hands, compared to its average volume of 281,560. The stock's fifty day moving average is $7.41 and its 200-day moving average is $6.53. Enanta Pharmaceuticals has a 52-week low of $4.09 and a 52-week high of $13.43. The company has a market cap of $177.76 million, a P/E ratio of -1.94 and a beta of 0.88.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.40. The firm had revenue of $18.31 million for the quarter, compared to analysts' expectations of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%.

Institutional Investors Weigh In On Enanta Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. US Bancorp DE purchased a new stake in shares of Enanta Pharmaceuticals during the first quarter valued at approximately $36,000. GAMMA Investing LLC bought a new position in shares of Enanta Pharmaceuticals during the 1st quarter valued at approximately $40,000. Tower Research Capital LLC TRC raised its holdings in Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 2,274 shares during the period. Farther Finance Advisors LLC boosted its stake in Enanta Pharmaceuticals by 11,558.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 5,779 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in Enanta Pharmaceuticals in the 4th quarter worth $66,000. Hedge funds and other institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.